Summary of King Oyster
Primary Information, Benefits, Effects, and Important Facts
King Oyster mushrooms are a species of the Pleurotus family of mushrooms, and related to regular Oyster mushrooms. They have a large stem that confers a relatively 'meaty' or 'hearty' flavor (Umami) and are seen as a medicinal mushroom.
Not too many studies are conducted on King Oyster mushrooms, but they appear to have the same properties of regular bioactive mushrooms in the sense that they interact with the immune system and may 'boost' immunity to sickness. King Oysters seem to be more potent at suppressing fatty acid absorption relative to other mushrooms according to one study, and have been implicated in increasing testosterone 5-fold. This latter study was conducted with very high doses (15-20% of feed) and was conducted in elk (out of all research animals, elk) and has not been replicated.
It also appears to be more estrogenic and bone protective in animal forms of menopause than other medicinal mushrooms tested.
Tired of all the misinformation spread by supplement companies?
Learn what works, what's a waste, and how to achieve your health goals with our free supplement mini-course.
Things To Know & Note
Some people may suffer allergic reactions to King Oyster mushrooms, and this would affect both supplementation as well as food. Do not use King Oyster Supplements if you have a known mushroom allergy
How to Take King Oyster
Recommended dosage, active amounts, other details
At this moment in time, all that can be recommended is to consume the fruiting body or stem of the King Oyster mushroom in your diet if you want the effects. Supplementation would work fine (and if we take motifs from other Bioactive Mushrooms would be around 1-3g daily) but minimal human studies have been conducted.
Scientific Research on King Oyster
Click on any below to expand the corresponding section. Click on to collapse it.
King Oyster is one of several Bioactive Mushroom also used as a food product with the phylogenic classification of Pleurotus eryngii. King Oyster varies from other 'Oyster' mushrooms, which are a different species (usually Pleurotus ostreatus). Pleurotus Eryngii appears to have multiple varieties; var. eryngii, var. ferulae, var. tingitanus, and var. nebrodensis although the last variety, nebrodensis, appears to have been elevated to a new species.
It is widespread in the Mediterranean, central Europe, northern Africa, and Asia. It is reported to have a pleasant taste and is used in culinary dishes.
As a mushroom, King Oyster is similar to many Herbal Supplements in the sense that it contains a variety of bioactives such as:
A hemolysin with two components, Erylysin A and Erylysin B; not heat stable at 37°C for 5 hours
Up to 8 different sterol compounds
Dietary protein, with up to 1.88-2.65% of total fresh weight as protein (and 5.3% nitrogen content)
Dietary lipids, at around 0.8% fresh weight
Dietary Minerals such as Calcium (74.28+/-0.04mcg/g), Copper (7.474+/-0.002mcg/g), Zinc (27.91+/-0.01), Sodium(678+/-0.2mcg/g), Magnesium (740+/-230mcg/g), Potassium (17.6+/-4.2mg/g), Phosphorus (9.0+/-2.6mg/g), and Sulfur(4.5+/-1.3mg/g).
It is quite unheard of to see such a large and round molecule; quite an interesting structure. It appears that two of the center molecules, the 1,2-dihydromintlactones, may unhinge at the 4 carbon and form this cyclic structure
A study conducted in elk using the industrial byproducts of King Oyster mushroom (19.92% beta-glucan content in this study) noted that high doses (15% and 20%) of King Oyster in the diet, over a period of 80 days, was able to increase circulating testosterone five-fold (0.2ng/mL to 1.0ng/mL) with no influence on thyroxine, GH, or IGF. This was accompanied by an increase in monocytes (+59%, 0.22-0.35K/ul but not dose-dependent) and hematocrit (+8.9%) yet with no liver abnormalities (ALT, AST) and in increase (+13%) in HDL-C.
King Oyster does contain sterol molecules, which structurally are usually related to testosterone, but no studies have been done on the possible link.
A study in ovariectomized (without ovaries) rats with 0.3% ethanolic extract of King Oyster daily, over 75 days, appeared to slightly increase uterine weight (much less than estradiol as active control) and reduce bone loss relative to control; indicative of estrogenic effects.
When tested in vitro, 0.1ug/mL of King Oyster was equally effective as 10nM of estradiol in proliferating MCF-7 cells, a test for estrogenicity, with statistically significant increases being seen as low as 0.001ng/mL. Interestingly, when an estrogen receptor antagonist was added it significantly reduced the proliferation but 10ug/mL King Oyster still induced proliferation above control cells.
When tested against other Bioactive mushrooms at a concentration of 1.0ug/mL, King Oyster appeared to be the most estrogenic (as assessed by increased cell proliferation) of the 14 tested; nonsignificantly different than Agaracus Blazei, Grifola frondosa (Maitake), Panellus serotinus and 3 other variants of Pleurotus and also nonsignificantly different than 100nM estradiol. Agaricus bisporus appeared to be slightly suppressive of division.
An ethanolic extract of King Oyster mushroom was found at 10-50ug/mL to inhibit IL-4 transcription in antigen-stimulated mast cells in a dose-dependent manner, suggestive of suppressing an allergic response. Reduction of NFAT and NF-kB activity, COX-2 mRNA and protein level, and NF-kB translocation due to reduction of IκB-α degradation, were also seen in these cells; all of which may have been downstream from inhibiting FcεRI signalling (with SyK signalling unaffected).
Due to these inhibitory effects, less pro-inflammatory cytokines were released from antigen-stimulated mast cells such as TNF-α, IL-1 and IL-6 alongside IL-4.
In ApoE-/- mice, King Oyster at 3% of the food intake by weight for 16 weeks trended towards reducing triglycerides and total cholesterol in mice but only reached statistical significance at 12 weeks with triglycerides (and became nonsignificant at 16 weeks again). These trends were on par with the two other groups of Maitake and Bunashimeji mushrooms, yet all groups were able to reduce the area of artherosclerotic lesions with Bunashimeji being the most potent. This study appears to not be related to dietary fiber inhibiting cholesterol uptake, as dietary cholesterol was controlled (0.066%) and Bunashimeji outperformed Maitake despite Maitake having the highest fiber content.
When tested in vitro, the water extract of King Oyster appeared to be the most potent in inhibiting pancreatic lipase activity out of 8 tested medicinal mushrooms. The water and ethanolic extract brought lipase activity down to 20.8% and 89.6% of activity (respectively) while Yamabushitake scored 95.9% and 68.4% (water/ethanolic) and Maitake to 76.5% with an ethanolic extract (water extract appeared to stimulate up to 113.3%, the worst inhibitory performance) and the methanolic extract of Sparassis Cripsa getting 65.4% of control. Heat treatment (cooking) did not affect the inhibition of King Oyster with up to 60 minutes of boiling, and administration of King Oyster to rats alongside fatty acids was able to reduce the AUC of the fats by 44%, which was attributed to inhibiting absorption due to no increase in LPL levels systemically (indicative of uptake).
When fed at 3% of the diet for up to 16 weeks, King Oyster is not associated with significant changes in triglycerides but only trends towards reductions.
King Oyster has been investigated for its cytotoxic effects due to belonging to the Pleurotus family, commonly associated with anti-cancer effects.
Eryngiolide A has demonstrated cytotoxicity against HeLa and HepG2 cells with IC50 values of 20.6μM and 28.6μM, respectively, which is classified as moderate cytotoxicity.
Mushrooms tend to have anti-oxidant capabilities, and when compared against 9 other species at 1mg ethanolic extract (including regular Oyster mushrooms, Pleurotus ostreatus) it was found that King Oysters scored 11.45% inhibiting on a DPPH free radical scavenging test, placing 7th out of 10 behind Morchella elata (59.22%) and Meripilus giganteus (43.12%), although ahead of regular Oyster Mushrooms (6.11%). This was given an inhibition value of 3.01 TOC (alpha-tocopherol equivalents, measured in ug/mL). A 1:3 methanolic extract of King Oyster, when tested against Morchella elata again and three new mushrooms still underperformed relatively on anti-oxidative assays.
A water extract of King Oyster has been shown, in vitro, to increase Alkaline Phosphatase activity at 0.08-10ul/mL concentrations (1.5 and 2-fold increases, respectively) and was able to delay the progression of osteoporosis ex vivo (in bones removed from mice) from 16% over 4 weeks in control to 8%. These effects may be secondary to estrogen-like activity, as a study in ovariectomized rats (to model menopause) found that 0.3% of an ethanolic extract of the fruiting bodies per day for 75 days of treatment had better bone mineral density relative to control by 14% (with estrogen at 30ug/kg being 25% higher than control).
May be useful to menopausal women for reducing the risk of osteoporosis, but appears to be estrogenic
- Reis FS, et al. Antioxidant properties and phenolic profile of the most widely appreciated cultivated mushrooms: a comparative study between in vivo and in vitro samples. Food Chem Toxicol. (2012)
- A pluralistic approach in the study of Pleurotus species with emphasis on compatibility and physiology of the European morphotaxa.
- Stajić M, Vukojević J, Duletić-Lausević S. Biology of Pleurotus eryngii and role in biotechnological processes: a review. Crit Rev Biotechnol. (2009)
- Typification of Pleurotus nebrodensis.
- Wang SJ, et al. Eryngiolide A, a Cytotoxic Macrocyclic Diterpenoid with an Unusual Cyclododecane Core Skeleton Produced by the Edible Mushroom Pleurotus eryngii. Org Lett. (2012)
- Shibata T, et al. Isolation and characterization of a novel two-component hemolysin, erylysin A and B, from an edible mushroom, Pleurotus eryngii. Toxicon. (2010)
- Arima J, et al. Eryngase: a Pleurotus eryngii aminopeptidase exhibiting peptide bond formation activity. Appl Microbiol Biotechnol. (2010)
- Ngai PH, Ng TB. A hemolysin from the mushroom Pleurotus eryngii. Appl Microbiol Biotechnol. (2006)
- Wang H, Ng TB. Eryngin, a novel antifungal peptide from fruiting bodies of the edible mushroom Pleurotus eryngii. Peptides. (2004)
- Chu KT, Xia L, Ng TB. Pleurostrin, an antifungal peptide from the oyster mushroom. Peptides. (2005)
- Lee IS, et al. Pleurone, a novel human neutrophil elastase inhibitor from the fruiting bodies of the mushroom Pleurotus eryngii var. ferulae. J Antibiot (Tokyo). (2011)
- Mushrooms of Genus Pleurotus as a Source of Dietary Fibres and Glucans for Food Supplements.
- Carbonero ER, et al. Unusual partially 3-O-methylated alpha-galactan from mushrooms of the genus Pleurotus. Phytochemistry. (2008)
- Liu X, et al. Extraction and antioxidant activities of intracellular polysaccharide from Pleurotus sp. mycelium. Int J Biol Macromol. (2010)
- Yaoita Y, et al. New sterols from two edible mushrooms, Pleurotus eryngii and Panellus serotinus. Chem Pharm Bull (Tokyo). (2002)
- Chou PY, et al. Glass distilling collector applied for HCN recovery from submerged culture broth and fruiting body of Pleurotus eryngii for identification and quantification. J Agric Food Chem. (2006)
- Zeng X, et al. Antioxidant capacity and mineral contents of edible wild Australian mushrooms. Food Sci Technol Int. (2012)
- Spent Mushroom Substrate Influences Elk (Cervus Elaphus Canadensis) Hematological and Serum Biochemical Parameters.
- Shimizu K, et al. Estrogen-like activity and prevention effect of bone loss in calcium deficient ovariectomized rats by the extract of Pleurotus eryngii. Phytother Res. (2006)
- Han EH, et al. Inhibitory effect of Pleurotus eryngii extracts on the activities of allergic mediators in antigen-stimulated mast cells. Food Chem Toxicol. (2011)
- Mori K, et al. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res. (2008)
- Mizutani T, et al. Hypolipidemic effect of Pleurotus eryngii extract in fat-loaded mice. J Nutr Sci Vitaminol (Tokyo). (2010)
- Kalyoncu F, et al. Antimicrobial and antioxidant activities of mycelia of 10 wild mushroom species. J Med Food. (2010)
- Kim SW, et al. Effects of mushroom, Pleurotus eryngii, extracts on bone metabolism. Clin Nutr. (2006)